Abstract Background Hypoxia-inducible factor 2α (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expression of proteins involved with angiogenesis, proliferation, and metastasis. Casdatifan is a potent, selective, orally bioavailable HIF-2α inhibitor that has demonstrat...
R. McKay, J. Merchan, A. Patnaik et al.· The Oncologist· 0 citations
Abstract Background The randomized, double-blind, phase 3 LITESPARK-022 study (NCT05239728) showed significant disease-free survival benefit with the addition of belzutifan to adjuvant pembrolizumab in participants with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence following surgery. We presen...
T. Powles, T. Choueiri, J. Karam et al.· The Oncologist· 0 citations
Abstract Background Previous retrospective work found an association between earlier immune-checkpoint inhibitors (ICI) infusion times and survival outcomes in renal cell carcinoma (RCC). A recent randomized trial in non-small cell lung cancer (NSCLC) also reported benefit, however, a recent analysis of several randomi...
P. Barrios, Mustafa Saleh, Liliana Ascione et al.· The Oncologist· 0 citations
Abstract Background Immune checkpoint inhibitor-based combinations represent the standard of care for advanced renal cell carcinoma (RCC). The OMNIVORE trial (NCT03652142) investigated a response-adaptive strategy including treatment discontinuation in early nivolumab responders (Arm A) and salvage ipilimumab addition...
M. Serzan, Wan-Ling Xie, B. McGregor et al.· The Oncologist· 0 citations
Abstract Background We sought to map the immunological landscape of metastatic renal cell carcinoma (RCC) in order to understand the mechanisms that dictate response to immune checkpoint inhibitors (ICI) and uncover biomarkers for ICI response. Methods We generated a single-cell RNA sequencing (scRNA-seq) atlas of the...
Ethan C. Burns, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhi...
Katrine N. Madsen, S. Kashima, H. Soulati et al.· Journal of Clinical Investig...· 0 citations
Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform t...
Mubin Tarannum, K. Dinh, Mila Stanojevic et al.· Cancer Discovery· 0 citations
BACKGROUND
The randomized phase III study KEYNOTE-564 (NCT03142334) established pembrolizumab after surgery as the standard of care for patients with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence. Prior analyses showed significantly improved disease-free survival (DFS) and overall survival (OS...
N. Haas, T. Powles, P. Tomczak et al.· Annals of Oncology· 1 citation
A randomized, multicenter, open-label phase 3 LITESPARK-033 study is designed to evaluate the efficacy and safety of belzutifan plus zanzalintinib versus cabozantinib in participants with advanced clear cell RCC who experienced recurrence during or after anti–PD-(L)1 adjuvant therapy.
T. Choueiri, T. Powles, M. Voss et al.· The Oncologist· 0 citations
Abstract Background For patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have relapsed after anti-programmed death protein 1 (anti–PD-1) or anti-programmed death ligand-1 (anti–PD-L1) treatment, second-line treatment options remain limited, consisting primarily of tyrosine kinase inhibit...
T. Choueiri, S. Pal, R. McKay et al.· The Oncologist· 0 citations
Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...
É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al.· The Oncologist· 0 citations
Abstract Background Chromophobe renal cell carcinoma (ChRCC) is traditionally defined by its unique metabolic reprogramming, including an increase in mitochondrial mass. The mitochondrial plasma proteome of metastatic ChRCC has been recently reported (Steiner et al. Cancers 2026), and we defined a two-protein signature...
Tie-Gang Han, Clara Steiner, Steven Safi et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
